Treatment of Metastatic Breast Carcinoma Refractory to Doxorubicin with Liposomal-Annamycin.

Abstract

Annamycin is a non-cross resistant doxorubicin analog that is formulated in a liposomal carrier. We have completed a phase I study and initiated a phase II study of liposomal Annamycin in patients with metastatic breast carcinoma. The maximum tolerated dose was 210/mg/m2. The limiting toxicity was myelosuppression. Other toxicities were limited to allergic reactions. No significant cardiotoxicity, alopecia, mucositis, nor gastrointestinal toxicity have been observed. No antitumor responses were observed in the Phase I study. Three patients have been accrued in the Phase II study. Tumor tissue is being stored for determination of MDR-1 and MRP status at baseline and after therapy.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 1997
Accession Number
ADA341569

Entities

People

  • Roman Perez-soler

Organizations

  • University of Texas at Austin

Tags

DTIC Thesaurus Topics

  • Antineoplastic Agents
  • Breast Cancer
  • Chemical Synthesis
  • Chemistry
  • Health Services
  • Medical Personnel
  • Oncology
  • Skin Diseases

Fields of Study

  • Medicine

Readers

  • Clinical Trial Research.
  • Oncology (Cancer Research).
  • Toxicology/Environmental Toxicology